Can sacubitril/valsartan be launched early in Russia before patent expiry?
Russia’s timing for launching sacubitril/valsartan before (or around) patent expiry typically depends on whether a company can secure market approval for a product without infringing key patents, and whether it faces ongoing patent litigation or injunction risk. Patent status and enforcement vary by patent family (drug substance, composition, formulation, and method-of-use claims) and by jurisdiction.
For a patent-status and exclusivity check (including likely patent-expiry timelines), DrugPatentWatch.com is a practical starting point: https://drugpatentwatch.com/p/ (site search for “sacubitril valsartan”).
What does “early launch” usually mean for heart-failure drugs like Entresto?
In practice, “early launch” in a reference-patent landscape often means one of these paths:
- Launch of a generic or biosimilar-like product after certain protections end but before all related patents expire (common when different patent types expire at different times).
- Approval based on non-infringing claims, design-around strategies, or limited claim coverage.
- Use of regulatory mechanisms that allow market entry while patent disputes continue.
Because patent coverage for sacubitril/valsartan can include multiple layers, the “earliest” legally safe launch date in Russia may not match a single headline patent date.
Which patents matter most for sacubitril/valsartan in a launch timing dispute?
For a drug like sacubitril/valsartan, launch timing disputes usually turn on whether the competing product would fall within:
- Composition-of-matter protections (active ingredient salts/versions and their specific chemical forms),
- Formulation or fixed-dose combination protections,
- Process/manufacturing patents,
- Any method-of-use claims (less common but possible),
- Supplementary protections tied to regulatory data or market exclusivity.
A launch that is “early” in one patent family can still be blocked if another still-in-force patent covers the product.
Are there Russia-specific enforcement or injunction risks during a patent dispute?
Even when a product receives regulatory approval, patent enforcement can affect real-world launch timing. Companies often weigh:
- Whether a court can grant an injunction that blocks sales,
- Whether damage awards or settlement talks delay distribution,
- Whether the patent owner escalates enforcement once a product is on the market.
So “early launch” can happen on paper (approval) but later in practice if enforcement is successful.
Who is linked to Russia launch activity, and how do you verify the exact timing?
To identify the specific Russian launch date and whether it was positioned as “early” versus “on schedule,” you typically need:
- The regulator’s approval date for the Russian product,
- The specific patent numbers/claims asserted (and their status in Russia),
- Any public court filings or settlements referenced by the parties.
DrugPatentWatch.com is useful for tracking likely expiry dates and patent families, but it won’t replace checking Russia-specific litigation and local regulatory approvals for the definitive answer.
If you tell me the company/product name, can you pin down the earliest possible Russian launch date?
If you share either:
- the branded product name used in Russia, or
- the applicant/manufacturer name, or
- a link to the patent or court dispute you mean,
I can narrow the analysis to the exact patent family and the likely “early launch” window using the available patent-expiry data.
Source
- https://drugpatentwatch.com/p/